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RESEARCH LETTER
Pulmonary tuberculosis:
Resistance pattern to ﬁrst line
Ultimately  the  study  population  was  affected  by  a  selection
bias,  typical  of  retrospective  studies.I
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Coimbra District, 2000--2011
Dear  Editor,
Drug  resistant  tuberculosis  (TB)  is  the  result  of  a  selec-
tive  pressure  on  the  Mycobacterium  tuberculosis, which  has
been  in  action,  over  the  last  70  years.
One  of  the  major  threats  to  the  control  of  TB  is  posed  by
the  development  and  spread  of  multidrug-resistant  strains
(MDR-TB)  that  are  resistant  to  at  least  isoniazid  (INH)  and
rifampicin  (RMP),  the  two  most  powerful  anti-TB  drugs
currently  available;  this  is  often  the  result  of  their  mis-
guided  use  and  poor  investment  in  control  programs.1,2
These  patients  eliminate  bacillus  for  a  longer  period,  which
increases  the  dissemination  risk  of  this  disease,  posing  an
alarming  problem  for  Public  Health.  Their  treatment  is  more
difﬁcult  to  manage  due  to  increased  morbidity  and  higher
costs.
This  growing  concern  led  to  the  development  of  this
study,  in  order  to  assess  the  resistance  patterns  to  ﬁrst  line
anti-TB  drugs  among  pulmonary  (respiratory)  TB  cases  noti-
ﬁed  and  residing  in  the  Coimbra  District  (Portugal)  between
2000  and  2011  and  to  determine  among  them  the  risk  factors
for  MDR-TB.
The  study  was  designed  as  a  retrospective  cohort  one.
It  was  carried  out  at  the  Respiratory  Diagnostic  Centres  of
Coimbra  and  Figueira  da  Foz.  1057  TB  cases  were  reviewed.
Pulmonary  TB  was  the  most  frequently  reported  diagnostic
site  (744/1057),  of  which  556  cases  resided  in  Coimbra  Dis-
trict.  Clinical  records  were  reviewed,  in  order  to  analyze
data  on  all  veriﬁed  culture  positive  Mycobacterium  tuber-
culosis  complex  (MTC)  cases  along  with  drug  susceptibility
testing  (DST).  Although  428  cases  were  registered  as  culture-
positive,  of  which  389  cases  had  MTC  registered  on  their
ﬁles,  only  339  had  a  registered  reference  (clinical  or  labora-
tory  archive)  to  DST  for  ﬁrst-line  drugs  (study  population).
There  were  15  cases  diagnosed  when  treated  with  a  full
course  of  anti-TB  treatment,  45  exclusively  with  a  biopsy,Please  cite  this  article  in  press  as:  Eufrásio  R,  e
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and  157  DST  results  unavailable  and/or  unregistered  due  to
technical  and  administrative  reasons.  The  adjusted  propor-
tion  of  cases  with  registered  DST  was  of  68.3%  (339/496).
(
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2173-5115/© 2016 Sociedade Portuguesa de Pneumologia. Published by 
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)The  ﬁrst  line  anti-TB  drugs  considered  for  this  study  were:
NH,  RMP,  ethambutol  (EMB),  pyrazinamide  (PZA)  and  strep-
omycin  (SM).
There  were  six  study  variables:  socio-demographic,  co-
orbidities,  risk  groups  (alcohol,  tobacco  smoke  and/or
rug  abuse,  residents  in  community  shelters,  homeless,  and
risoners),  previous  treatment  history  (for  disease  or  latent
nfection),  drug  susceptibility  result,  and  resistance  pat-
ern.  In  order  to  determine  independent  risk  factors  for  MDR
ulmonary  TB,  categorical  data  were  compared  by  the  chi-
quare  test  or  the  ﬁsher  exact  test.  A  p  value  of  less  than
.05  was  considered  as  statistically  signiﬁcant.
The  study  population  enrolled  73.2%  (248/339)  male
atients.  The  median  age  of  the  patients  was  43  years,  with
 minimum  and  maximum  of  18  and  90  years,  respectively.
HIV  screening  status  was  registered  in  only  32.1%
109/339)  of  the  patients  selected.  Of  those  109  patients,
5  were  HIV  positive,  of  whom  8  were  foreign-born.
Considering  the  difﬁculty  of  growth-based  testing  for
ZA,  its  DST  was  unavailable  in  5.5%  (19/339)  of  the  cases.
here  was  one  case  without  registered  DST  for  SM  (Table  1).
Among  those  enrolled,  17.1%  were  resistant  to  at  least
ne  anti-TB  drug.  The  drug  resistance  observed  for  any  of
he  ﬁrst  line  drugs  in  new  and  previously  treated  patients
as  7.8%  and  29%  to  INH,  0.6%  and  12.9%  to  RMP;  1%  and
.5%  to  EMB;  1%  and  9.7%  to  PZA;  11.4%  and  25.8%  to  SM,
espectively  (Table  1).
The  cases  resistant  to  at  least  one  ﬁrst  line  anti-TB  drug
eaked  by  32.3%  (10/31)  in  2006.  Those  susceptible  to  all
rst-line  anti-TB  drugs  peaked  by  88.5%  (23/26)  in  2009.  The
esistance  to  INH  and  RMP  peaked  in  2006,  with  19.4%  (6/31)
nd  6.5%  (2/31),  respectively;  to  EMB  peaked  in  2011,  with
0%  (2/20);  to  PZA  peaked  in  2003,  with  8.6%  (3/35);  and  to
M  in  2006,  with  29%  (9/31).  There  were  six  patients  identi-
ed  with  MDR  pulmonary  TB  over  the  study  period;  with  the
ighest  incidence  of  6.9%  (2/31)  in  2006.
Resistance  to  PZA  was  reported  in  0.9%  (3/314)  and  50%
3/6)  of  non  and  MDR-TB  cases,  respectively.  The  association
f  MDR-TB  with  previous  treatment  history  was  signiﬁcant
ith  an  odds  ratio  of  22.7  (95%  CI;  3.9--1294;  p-value,  0.001)t  al.  Pulmonary  tuberculosis:  Resistance  pattern
 District,  2000--2011.  Rev  Port  Pneumol.  2016.
Table  2).
The  overall  resistance  to  SM  (12.7%)  was  the  most  preva-
ent  among  the  ﬁrst  line  anti-TB  drugs.  It  might  be  due  to
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Table  1  First  line  anti-tuberculosis  drug  resistance  proﬁle  in  new  and  previously  treated  patients.
Total  number  of  pulmonary
TB  patients  =  556
Previous  anti-TB  treatment  status
New  Previously  treated  Total
Cases (%)  Cases  (%)  Cases  (%)
I  Total  DST  results  308  (90.9)  31  (9.1)  339  (61.0*)
Any  resistance  to  INH  24  (7.8)  9  (29.0)  33  (9.7)
Any resistance  to  RMP  2  (0.6)  4  (12.9)  6  (1.8)
Any resistance  to  EMB  3  (1.0)  2  (6.5)  5  (1.5)
Any resistance  to  PZA 3  (1.0)  3  (9.7)  6* (1.8*)
Any resistance  to  SM 35  (11.4) 8  (25.8) 43** (12.7**)
II Mono-resistance
INH  10  (3.2) 2  (6.4) 12  (3.5)
RMP 0  0  0
EMB 1  (0.32)  0  1  (0.3)
PZA 1  (0.32)  0  1  (0.3)
SM 20  (6.5)  1  (3.2)  21  (6.2)
Total 32 (10.4) 3  (9.6)  35  (10.3)
III Poly-resistance
INH  +  SM  12  (3.9)  2  (6.5)  14  (4.1)
EMB +  SM  1  (0.32)  0  1  (0.3)
PZA +  SM  1  (0.32)  0  1  (0.3)
INH +  PZA  +  SM  0  1  (3.2)  1  (0.3)
Total 14  (4.54)  3  (9.7)  17  (5.0)
IV MDR
INH  +  RMP  +  EMB  +  PZA  +  SM  0  2  (6.5)  2  (0.6)
INH +  RMP  +  EMB  +  SM  1  (0.32)  0  1  (0.3)
INH +  RMP  +  SM  0  2  (6.5)  2  (0.6)
INH +  RMP  +  PZA  1  (0.32)  0  1  (0.3)
Total 2  (0.64)  4  (13.0)  6  (1.8)
* 19 ND (5.6%).
** 1 ND (0.3%).
INH -- isoniazid, RMP -- rifampicin, EMB -- ethambutol, PZA -- pyrazinamide, SM -- streptomycin, DST -- drug susceptibility testing, MDR --
Multidrug resistance, ND -- non determined.
Table  2  MDR-TB  risk  factors  among  pulmonary  TB  cases  in  Coimbra  District,  2000--2011.
Independent  variables  Drug  susceptibility  Odds  ratio
CI  (95%)
p  value
Non-MDR
Cases
MDR
Cases
HIV  infection  (n  =  109)  24  1  3.458  (0.208--57.373)  0.408
Alcohol users  (n  =  338)  88  3  2.773  (0.549--13.993)  0.349
Drug addiction  (n  =  339)  31  1  1.948  (0.221--17.212)  0.451
Prisoners (n  =  339)  7  1  9.314  (0.959--90.503)  0.134
Tobacco smokers  (n  =  339)  126  4  3.286  (0.593--18.199)  0.208
COPD (n  =  339)  14  1  4.557  (0.499--41.655)  0.239
Previous treatment  history  (n  =  339)  27  4  22.667  (3.969--129.449)  0.001
Immigrant (n  =  339)  34  2  4.397  (0.776--24.903)  0.125
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tHIV -- human immunodeﬁciency virus; COPD -- chronic obstructive
p -- chi-square test or the ﬁsher exact test.
ts  prolonged  availability  that  dates  from  1940s,  which  hasPlease  cite  this  article  in  press  as:  Eufrásio  R,  e
to  ﬁrst  line  anti-tuberculosis  drugs  in  the  Coimbra
http://dx.doi.org/10.1016/j.rppnen.2016.04.001
ead  to  the  development  of  resistant  strains.3
PZA  is  an  important  component  of  TB  treatment,  hav-
ng  remarkable  sterilizing  effects  in  killing  semidormant  TB
acilli.  Its  resistance  pattern  was  similar  to  that  reported  in
r
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oonary disease;
he  United  States  (2.2%  and  38%  of  non  and  MDR-TB  cases,t  al.  Pulmonary  tuberculosis:  Resistance  pattern
 District,  2000--2011.  Rev  Port  Pneumol.  2016.
espectively).4
The  prevalence  of  strains  with  primary  resistance  to  INH
s  a  very  important  indicator  to  estimate  the  risk  of  devel-
pment  of  MDR.3,5 Over  the  study  period,  its  value  was  of
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7.8%,  below  the  European  Union  average  (8.1%).3 However,
resistance  to  INH  among  previously  treated  patients  was  the
most  prevalent  (29%).
The  overall  resistance  to  RMP  has  a  high  positive  predic-
tive  value  to  MDR,  once  all  cases  are  MDR-TB.
In  Portugal,  the  incidence  of  MDR-TB  has  been
decreasing,  representing  in  2009,  1.5%  of  the  total  cases
of  TB.6 Coimbra  District  is  one  of  the  regions  with  the  low-
est  incidences  of  the  disease;  there  were  no  notiﬁcations  of
MDR-TB  cases6 between  2009  and  2011.
Previous  treatment  was  recognized  as  the  strongest  risk
factor  for  MDR-TB  (Table  2),  which  is  also  observed  in
Europe.7
Delayed  recognition  of  drug  resistance,  inappropriate
chemotherapy  regimens,  inadequate  or  irregular  drug  sup-
ply,  poor  compliance  by  patients,  malabsorption  of  one  or
more  drugs,  and  sequestered  disease  (in  which  differen-
tial  penetration  of  anti-TB  drugs  may  lead  to  monotherapy)
have  been  reported  as  reasons  for  developing  drug  resistant
strains.7,8
Progressive  clinical  and/or  radiographic  deterioration  or
failure  of  cultures  to  convert  in  a  timely  fashion  while  the
patient  is  receiving  treatment  should  lead  to  the  antic-
ipation  of  treatment  failure,  and  possible  acquired  drug
resistance.9 Among  these  patients,  depending  upon  the  cir-
cumstances,  consideration  should  be  given  to  changing  the
treatment  regimen.  If  a  decision  is  made  accordingly,  the
essential  principle  is  to  add  at  least  two  new  drugs,  prefer-
ably  three,  to  which  the  organism  is  known  to  be  susceptible
or  those  that  the  patient  has  never  received  and  never  intro-
duce  just  a  single  drug  to  a  failing  regimen.9
The  change-over  from  supervised  sanatorium  treatment
to  unsupervised  domiciliary  treatment  has  affected  compli-
ance  signiﬁcantly.  In  Portugal  there  are  no  explicit  legal
grounds  on  which  to  enforce  TB’s  treatment  on  those  that
refuse  it,  and  certain  patients  are  extremely  difﬁcult  to
follow-up.  The  success  of  the  treatment  relies  in  a  rela-
tionship  based  on  mutual  trust;  therefore  it  is  extremely
important  that  the  medical  teams  do  not  underestimate
non-compliance  determinants.
When  compliance  is  difﬁcult  to  predict,  the  most  effec-
tive  method  of  drug  delivery  is  directly  observed  therapy
(DOT)  rather  than  self-administered  therapy.  The  provision
of  DOT  should  be  prioritized  to  (1)  suspected  or  proven  drug-
resistant  organisms,  (2)  treatment  failure,  (3)  documented
re-treatment  disease,  (4)  drug  abuse/homelessness,  (5)  sus-
pected  or  previous  non-compliance,  (6)  mental  illness,  (7)
sputum  smear  positive  for  acid-fast  bacteria,  (8)  HIV  co-
infection,  and  (9)  children.7--9
Although  affected  by  a  selection  bias,  the  HIV  co-
infection  did  not  appear  to  be  a  predisposing  factor  for
the  development  of  MDR-TB  (Table  2).  Global  surveys  sug-
gest  that  HIV  is  not  an  independent  risk  factor  for  the
development  of  drug  resistance.5 Many  MDR-TB  nosoco-
mial  outbreaks  have  been  reported  among  HIV  patients.7,10
However,  if  patients  with  HIV  infection  are  treated  appro-
priately,  it  is  not  evident  that  it  favors  the  transmission  of
MDR  strains,7,10 although  there  might  be  shared  risk  factors
between  them  (drug  injection,  homelessness,  hospitaliza-Please  cite  this  article  in  press  as:  Eufrásio  R,  e
to  ﬁrst  line  anti-tuberculosis  drugs  in  the  Coimbra
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tion  and  others).7
In  Coimbra  District  there  has  been  an  increase  of  the  pro-
portion  of  cases  resistant  to  at  least  one  ﬁrst  line  anti-TB PRESS
3
rug,  a  typical  feature  of  low  incidence  regions.  The  most
owerful  predictor  of  the  presence  of  MDR-TB  is  a  history  of
revious  treatment.  The  implications  of  our  ﬁndings  relat-
ng  to  RMP  support  the  restriction  of  its  use  to  protect  its
fﬁcacy.1--5
The  high  proportion  of  MDR-TB  cases  resistant  to  PZA
ighlights  an  important  alert,  because  it  can  become  an
mportant  public  health  problem,  as  PZA  is  an  essential
art  of  TB  treatment,  widely  used  for  both  drug-susceptible
nd  MDR-TB  treatment.  Thus,  its  DST  is  critical,  particu-
arly  among  MDR-TB  patients,  before  starting  or  adjusting
reatment  regimens.4
Overall  the  study  ﬁndings  emphasize  the  importance  of
ontinuing  to  prioritize  the  prevention  of  drug-resistant  TB
trains  from  developing  through:  (1)  continuous  epidemi-
logical  surveillance  in  order  to  monitor  drug  resistance
atterns;  (2)  prescription  of  appropriate  treatment;  and  (3)
ssurance  that  the  prescribed  regimen  is  complied  with,  and
hat  those  who  abscond  from  treatment  are  identiﬁed  early
nd  duly  supervised  under  DOT.
We  should  all  keep  in  mind  that  the  potential  to  induce
esistances  as  result  of  insufﬁcient  compliance  will  never  be
ompletely  overcome,  even  with  the  development  of  new
rugs.
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